Director, Bone Marrow Transplant Program Massachusetts General Hospital
Oncology
Dr. Thomas R. Spitzer, MD
|
|
Give Review
Thomas Spitzer practices Oncology. He graduated from University of Rochester School of Medicine and Dentistry. He has 6 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification", "Boston Herald" and "Super Doctor". Thomas R. Spitzer is a published doctor. He has 56 publications published. The most current publication "Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation." He is registered with Medicare and accepts Medicare payments.
Publications
- Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem Cell transplantation.
- Longitudinal Studies of a B Cell-Derived Signature of Tolerance in Renal Transplant Recipients.
- Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL.
- Increasing incidence of Chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
- Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem Cell transplantation.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Outcomes and management strategies for Graft failure after umbilical cord blood transplantation.
- Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem Cell transpl...
- Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression.
- Engraftment Syndrome after allogeneic hematopoietic cell transplantation in adults.
- Phase I Study of Urate Oxidase in the Reduction of Acute Graft-vs-Host Disease Following Myeloablative Allogeneic Stem Cell Transplantation.
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic Malignancies.
- Risk factors for invasive fungal Disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
- Chronic graft-versus-host disease with skin signs suspicious for squamous cell Carcinoma.
- Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
- Microtransplantation: a new paradigm for the separation of Graft versus host disease and Graft versus tumor?
- Edema and tetraparesis in a miniature pig after allogeneic hematopoietic Cell transplantation.
- Expression of ñ4ò7 integrin on memory CD8(+) T cells at the presentation of Acute intestinal GVHD.
- Lack of anti-donor allo-antibody does not indicate lack of immune sensitization; studies of Graft loss in a haploidentical-HCT swine model.
- The expanding frontier of hematopoietic Cell transplantation.
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
- Expression of CD30 in patients with Acute graft-vs.-host disease.
- Changing stripes to avoid graft versus Leukemia.
- Selection of optimal alternative Graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.
- Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU, and etoposide (CBV) followed by autologous stem Cell transplant.
- Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor Grafts.
- Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation.
- Translational studies in hematopoietic cell transplantation: Treatment of hematologic Malignancies as a stepping stone to tolerance induction.
- High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin Lymphoma.
- Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal Disease.
- Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to i...
- Hematopoietic stem cell transplantation in patients with Chronic kidney disease.
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-Cell transplantation for light chain amyloidosis and heart failure.
- Kidney Disease associated with plasma cell dyscrasias.
- Donor-derived second hematologic Malignancies after cord blood transplantation.
- Defibrotide for the treatment of severe hepatic veno-occlusive Disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding ...
- The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with Acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma.
- Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma: a single-institution exp...
- Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and Peripheral-blood monocytosis.
- Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of Acute intestinal graft-versus-host disease following allogeneic s...
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
- Light chains: heavy burden in kidney transplantation.
- HLA-mismatched renal transplantation without maintenance immunosuppression.
- Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated Lymphoma: AIDS Malignancy Consortium stud...
- Phase I trial of parathyroid hormone to facilitate stem Cell mobilization.
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
- Stable multilineage chimerism without Graft versus host disease following nonmyeloablative haploidentical hematopoietic cell transplantation.
- Protecting the Host naturally.
- Haploidentical stem Cell transplantation: the always present but overlooked donor.
- Transcriptional analysis of spo0A overexpression in Clostridium acetobutylicum and its effect on the Cell's response to butanol stress.
- Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.
- Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic Malignancies.
- Impact of prophylactic donor leukocyte infusions on mixed chimerism, Graft-versus-host disease, and antitumor response in patients with advanced hematologic malignanci...
- Induction of kidney alloGraft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease.
- Dose-escalated total body irradiation and autologous stem Cell transplantation for refractory hematologic malignancy.
Schools
University Of Rochester School Of Medicine and Dentistry
New York Hospital
Meml Hospital
Case Western Reserve University
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Boston Herald
- Super Doctor
Education
-
New York Presbyterian Hospital - Cornell Campus -
University of Rochester School of Medicine and Dentistry
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1477543783 | |
| NPPES Provider LastName | SPITZER | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 417.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477543783 |
| Last Name Of The Provider | SPITZER |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Elizabeth A. Guancial, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shrikanta Chattopadhyay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan Carlson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason A. Freed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam F. Binder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffery L. Kutok, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Sarah Schellhorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea J. Bullock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart R. Bless, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Levi A. Garraway, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jennifer S. Temel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn J. Bubley, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Adam Lerner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Einstein, MD |